News|Videos|August 1, 2024

Emerging Treatments in Mild/Moderate Multiple Sclerosis

Key opinion leaders examine the available data on Bruton tyrosine kinase (BTK) inhibitors to assess whether the evidence supports their efficacy as a treatment option for multiple sclerosis (MS).

BTK inhibitors: Do the current data suggest this strategy for mild MS?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.